Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00328458
Status:
COMPLETED
Last Update Posted:
2018-07-17
First Post:
2006-05-19
Brief Title:
EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University
Organization:
Thomas Jefferson University
Study Overview
Official Title:
A Phase I Open-label Dose-escalation Safety Study of the Combination of EPO906 and Radiation Therapy for the Treatment of Patients With Cancer
Status:
COMPLETED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients
Detailed Description:
To determine the maximum tolerated dose MTD of EPO906 administered in combination with radiation therapy and establish a recommend phase II dose
To evaluate the safety and toxicity profile of EPO906 when administered concurrently with radiotherapy in three disease cohorts
To evaluate tumor response
To evaluate the safety and toxicity profile of EPO906 when administered concurrently with radiotherapy in three disease cohorts
To evaluate tumor response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2003-33 | OTHER | CCRRC | None |